slotkoers
Dhaka S.E.
00:00:00 30-04-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
210,9
BDT
|
+1,39%
|
|
-0,85%
|
+0,29%
|
Fiscaal tijdperk: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Marktkapitalisatie
1 |
208.535
|
145.631
|
191.030
|
192.094
|
185.977
|
186.953
|
-
|
-
|
Bedrijfswaarde
1 |
208.535
|
113.067
|
147.770
|
140.679
|
137.870
|
186.953
|
186.953
|
186.953
|
K/w-verhouding
|
-
|
10,4
x
|
12
x
|
10,6
x
|
9,8
x
|
8,82
x
|
7,58
x
|
6,74
x
|
Dividendrendement
|
1,7%
|
2,86%
|
2,78%
|
4,61%
|
5%
|
4,86%
|
5,33%
|
5,93%
|
Marktkapitalisatie/omzet
|
4,74
x
|
3,17
x
|
3,77
x
|
3,34
x
|
2,96
x
|
2,6
x
|
2,31
x
|
2,06
x
|
Bedrijfswaarde/omzet
|
4,74
x
|
3,17
x
|
3,77
x
|
3,34
x
|
2,96
x
|
2,6
x
|
2,31
x
|
2,06
x
|
Bedrijfswaarde/EBITDA
|
12,9
x
|
8,72
x
|
10,6
x
|
9,5
x
|
9,01
x
|
8,22
x
|
7,21
x
|
6,42
x
|
Bedrijfswaarde/FCF
|
20,2
x
|
16,7
x
|
26,4
x
|
19,8
x
|
32,5
x
|
13,3
x
|
11,3
x
|
11,7
x
|
FCF Yield
|
4,96%
|
5,99%
|
3,78%
|
5,06%
|
3,08%
|
7,49%
|
8,86%
|
8,56%
|
Price to Book
|
2,87
x
|
1,79
x
|
2,1
x
|
1,86
x
|
1,61
x
|
1,47
x
|
1,32
x
|
1,19
x
|
Aantal aandelen (in duizenden)
|
886.451
|
886.451
|
886.451
|
886.451
|
886.451
|
886.451
|
-
|
-
|
Referentieprijs
2 |
235,2
|
164,3
|
215,5
|
216,7
|
209,8
|
210,9
|
210,9
|
210,9
|
Datum van publicatie
|
27-11-19
|
01-12-20
|
25-11-21
|
04-12-22
|
22-11-23
|
-
|
-
|
-
|
Fiscaal tijdperk: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Omzet
1 |
44.034
|
45.876
|
50.703
|
57.598
|
62.748
|
71.990
|
81.075
|
90.892
|
EBITDA
1 |
16.170
|
16.701
|
18.009
|
20.218
|
20.651
|
22.740
|
25.935
|
29.122
|
Bedrijfsresultaat (EBIT)
1 |
14.143
|
14.731
|
16.126
|
18.383
|
18.341
|
20.298
|
23.710
|
26.662
|
Operationele Marge
|
32,12%
|
32,11%
|
31,81%
|
31,92%
|
29,23%
|
28,2%
|
29,24%
|
29,33%
|
Resultaat voor belastingen (EBT)
1 |
-
|
16.998
|
18.756
|
21.025
|
21.099
|
25.436
|
28.834
|
32.467
|
Nettowinst (verlies)
1 |
-
|
13.354
|
14.743
|
16.417
|
18.858
|
21.495
|
24.667
|
27.725
|
Nettomarge
|
-
|
29,11%
|
29,08%
|
28,5%
|
30,05%
|
29,86%
|
30,42%
|
30,5%
|
WPA
2 |
-
|
15,82
|
17,99
|
20,51
|
21,41
|
23,90
|
27,83
|
31,28
|
Free Cash Flow
1 |
10.343
|
8.719
|
7.223
|
9.713
|
5.721
|
14.004
|
16.563
|
15.996
|
FCF-marge
|
23,49%
|
19%
|
14,25%
|
16,86%
|
9,12%
|
19,45%
|
20,43%
|
17,6%
|
Kasstroomconversie (ebitda)
|
63,96%
|
52,21%
|
40,11%
|
48,04%
|
27,71%
|
61,58%
|
63,86%
|
54,93%
|
Kasstroomconversie (nettowinst)
|
-
|
65,29%
|
48,99%
|
59,16%
|
30,34%
|
65,15%
|
67,15%
|
57,7%
|
Dividend per aandeel
2 |
4,000
|
4,700
|
6,000
|
10,00
|
10,50
|
10,25
|
11,25
|
12,50
|
Datum van publicatie
|
27-11-19
|
01-12-20
|
25-11-21
|
04-12-22
|
22-11-23
|
-
|
-
|
-
|
Fiscaal tijdperk: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Nettoschuldpositie
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
|
-
|
32.564
|
43.260
|
51.415
|
48.107
|
-
|
-
|
-
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
10.343
|
8.719
|
7.223
|
9.713
|
5.721
|
14.004
|
16.563
|
15.996
|
ROE (netto-inkomsten/eigen vermogen)
|
20,1%
|
18,4%
|
17,5%
|
18,7%
|
17,1%
|
17,3%
|
17,9%
|
18,1%
|
ROA (netto-inkomsten/totale activa)
|
19%
|
17,3%
|
16,6%
|
17,7%
|
16,1%
|
16,4%
|
17%
|
17,2%
|
Totale activa
1 |
-
|
76.983
|
88.636
|
92.778
|
116.787
|
131.468
|
145.100
|
161.192
|
Nettoactief per aandeel
2 |
81,90
|
91,60
|
103,0
|
117,0
|
130,0
|
144,0
|
160,0
|
178,0
|
Cashflow per aandeel
2 |
-
|
-
|
-
|
-
|
9,640
|
26,50
|
29,60
|
33,30
|
Capex
|
2.049
|
2.042
|
3.798
|
6.052
|
-
|
-
|
-
|
-
|
Capex/omzet
|
4,65%
|
4,45%
|
7,49%
|
10,51%
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
27-11-19
|
01-12-20
|
25-11-21
|
04-12-22
|
22-11-23
|
-
|
-
|
-
|
Laatste slotkoers
210,9
BDT Gemiddelde koersdoel
321,8
BDT Spread / Gemiddelde doel +52,56% Consensus |
Vaira. 1 jan.
|
Kapi.
|
---|
| +0,29% | 1,7 mld. | | +33,25% | 704 mld. | | +28,59% | 577 mld. | | -3,55% | 348 mld. | | +18,16% | 327 mld. | | +4,36% | 288 mld. | | +14,81% | 234 mld. | | +4,93% | 198 mld. | | -9,78% | 194 mld. | | -3,69% | 147 mld. |
Farmaceutische producten - Andere
|